ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
January 10 2016 - 6:30PM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
election of Alexander J. Denner, Ph.D., as chairman of its board of
directors in a unanimous vote effective January 8, 2016. Dr. Denner
joined the ARIAD Board of Directors in February 2014 and most
recently led the Board’s search committee to select the Company’s
new CEO Paris Panayiotopoulos.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160110005030/en/
Alexander J. Denner, Ph.D (Photo:
Business Wire)
“I am honored to serve ARIAD’s shareholders as Chairman of the
Board,” said Dr. Denner. “ARIAD has extremely valuable assets and
highly dedicated employees. I am excited to work with Paris, our
new CEO, and his team to bring a new level of accountability to the
company and a renewed focus on value creation as ARIAD strives to
improve the lives of cancer patients.”
Dr. Denner is the Chief Investment Officer and founding partner
of Sarissa Capital Management which focuses on improving the
strategies of companies to better provide shareholder value. Dr.
Denner also serves as a director of Biogen Inc. Dr. Denner received
his S.B. degree from the Massachusetts Institute of Technology and
his M.S., M.Phil., and Ph.D. degrees from Yale University.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough
medicines. ARIAD is working on new medicines to advance the
treatment of various forms of chronic and acute leukemia, lung
cancer and other difficult-to-treat cancers. ARIAD utilizes
computational and structural approaches to design small-molecule
drugs that overcome resistance to existing cancer medicines. For
additional information, visit http://www.ariad.com or follow
ARIAD on Twitter (@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements, each of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein which do not describe historical
facts, including, but not limited to, some of statements made by
Dr. Denner, are forward-looking statements that are based on
management's expectations and are subject to certain factors, risks
and uncertainties that may cause actual results, outcome of events,
timing and performance to differ materially from those expressed or
implied by such statements. These factors, risks and uncertainties
include, but are not limited to, our ability to meet anticipated
clinical trial commencement, enrollment and completion dates and
regulatory filing dates for our products and product candidates and
to move new development candidates into the clinic; our ability to
execute on our key corporate initiatives; regulatory developments
and safety issues, including difficulties or delays in obtaining
regulatory and pricing and reimbursement approvals to market our
products; our ability to successfully commercialize and generate
profits from sales of Iclusig or our other product candidates,
including brigatinib, if approved; competition from alternative
therapies; our reliance on the performance of third-party
manufacturers and specialty pharmacies for the distribution of
Iclusig; the occurrence of adverse safety events with our products
and product candidates; the costs associated with our research,
development, manufacturing and other activities; the conduct,
timing and results of preclinical and clinical studies of our
products and product candidates, including that preclinical data
and early-stage clinical data may not be replicated in later-stage
clinical studies; the adequacy of our capital resources and the
availability of additional funding; patent protection and
third-party intellectual property claims; risks related to key
employees, markets, economic conditions, health care reform, prices
and reimbursement rates; and other risk factors detailed in our
public filings with the U.S. Securities and Exchange Commission,
including our most recent Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160110005030/en/
ARIAD Pharmaceuticals, Inc.For InvestorsMaria Cantor,
617-680-9452Maria.cantor@ariad.comorFor MediaLiza Heapes,
617-621-2135Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024